

# Resource Summary Report

Generated by SPARC SAWG on Aug 18, 2026

## CD223 (LAG-3)

RRID:AB\_2742438

Type: Antibody

### Proper Citation

BD Biosciences Cat# 744727, RRID:AB\_2742438

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2742438](http://antibodyregistry.org/AB_2742438)

**Proper Citation:** BD Biosciences Cat# 744727, RRID:AB\_2742438

**Target Antigen:** CD223 (LAG-3)

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: Flow cytometry

**Antibody Name:** CD223 (LAG-3)

**Description:** This monoclonal targets CD223 (LAG-3)

**Target Organism:** human

**Clone ID:** T47-530

**Antibody ID:** AB\_2742438

**Vendor:** BD Biosciences

**Catalog Number:** 744727

**Record Creation Time:** 20250819T232127+0000

**Record Last Update:** 20250820T050528+0000

### Ratings and Alerts

No rating or validation information has been found for CD223 (LAG-3).

No alerts have been found for CD223 (LAG-3).

## Data and Source Information

**Source:** [Antibody Registry](#)

## Usage and Citation Metrics

We found 4 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [SPARC SAWG](#) .

Jassowicz L, et al. (2026) Dissecting the cellular architecture of breast cancer brain metastases reveals prognostically distinct immune landscapes. Cancer cell, 44(6), 1290.

Vyasamneni R, et al. (2023) A universal MHCII technology platform to characterize antigen-specific CD4+ T??cells. Cell reports methods, 3(1), 100388.

Awad MM, et al. (2022) Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer cell, 40(9), 1010.

Sosa Cuevas E, et al. (2022) Diversification of circulating and tumor-infiltrating plasmacytoid DCs towards the P3 (CD80+ PDL1-)-pDC subset negatively correlated with clinical outcomes in melanoma patients. Clinical & translational immunology, 11(5), e1382.